SLC5A2 and heart failure: Importantly, most patients in these studies were already receiving optimized standard-of-care therapies, including β-blockers and mineralocorticoid receptor antagonists, which enhances the generalizability of the findings and provides valuable insight into the additive role of SGLT2 inhibitors and ARNIs in contemporary heart failure management.